European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.","authors":"Maximilian J Mair, Sabrina Hartenbach, Erwin Tomasich, Sybren L N Maas, Sarah A Bosch, Georg Widhalm, Franziska Eckert, Felix Sahm, Johannes A Hainfellner, Markus Hartenbach, Anna S Berghoff, Matthias Preusser, Nathalie L Albert","doi":"10.1007/s00259-025-07075-8","DOIUrl":"10.1007/s00259-025-07075-8","url":null,"abstract":"<p><strong>Purpose: </strong>High-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas is unclear, as data on target expression is scarce.</p><p><strong>Methods: </strong>CNS WHO grade 2 and 3 meningioma samples were immunohistochemically stained for somatostatin receptor 2a (SSTR2a), fibroblast activation protein (FAP), and human epidermal growth factor receptors 2/3 (HER2/HER3). Target expression was correlated with (epi-)genetic tumour subtyping by DNA methylation analysis, genetic alterations, and survival.</p><p><strong>Results: </strong>Meningioma samples of 58 patients were included. SSTR2a expression (membranous/cytoplasmic) was observed in 43/55 (78.2%), and FAP expression in 15/58 (25.9%) evaluable samples, with HER2 and HER3 expression in one specimen each (1.7%). Membranous SSTR2a expression was strong in 18 (32.7%), intermediate in 12 (21.8%), and weak in 11 (20.0%) samples. While SSTR2a expression was more homogenous and mainly seen in regions with higher cellularity, FAP immunoreactivity was predominantly seen in tumour stroma and regions of lower cellularity. SSTR2a immunoreactivity was associated with TRAF7 wildtype status (p = 0.034). FAP expression was more frequent in meningiomas of CNS WHO grade 3 (vs. CNS WHO 2; p < 0.001), and samples with NF2 mutations (p = 0.032) or CDKN2A/B deletions (p = 0.013) compared to wildtype. FAP and SSTR2a expression (present vs. absent) were not associated with overall survival (p > 0.05).</p><p><strong>Conclusion: </strong>SSTR2a and FAP are expressed in high-grade meningioma samples to a variable extent, and differences across meningioma subtypes underscore the need for biomarkers to improve patient selection. Spatial heterogeneity of target expression should be considered in radioligand therapy design.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2771-2781"},"PeriodicalIF":8.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings.","authors":"Sijuan Zou, Zheng Liu, Jianyuan Zhou, Shuang Song, Dongdong Wang, Dongling Zhu, Siyuan Cheng, Zhaoting Cheng, Yuankai Zhu, Tianci Yu, Donghui Pan, Min Yang, Xiaohua Zhu","doi":"10.1007/s00259-025-07142-0","DOIUrl":"10.1007/s00259-025-07142-0","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Recently, novel human epidermal growth factor receptor 2 antibody-drug conjugate therapies have shown remarkable efficacy in treating urothelial carcinoma, highlighting the growing need for comprehensive assessment of HER2 expression in tumors to identify patients who could benefit. However, non-invasive methods for assessing HER2 status in patients with urothelial carcinoma remain limited. This study aimed to preliminarily evaluate the clinical potential of [68Ga]Ga-HER2 affibody PET/CT for non-invasive assessment of HER2 expression in patients with urothelial carcinoma.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;A cohort of 25 patients with urothelial carcinoma was retrospectively included from a prospective parent study (NCT05535621), and sequential PET/CT using [68Ga]Ga-HER2 affibody and [18 F] FDG was performed. HER2 status was assessed through pathological evaluation using immunohistochemistry, with scoring categories of 0, 1+, 2+, and 3+. Lesion uptake on PET/CT was quantified using the maximum standardized uptake value (SUVmax). Comparisons of SUVmax between primary tumor groups with different HER2 expression levels (HER2-positive IHC 2+, 3 + vs. HER2-negative IHC 0, 1+, and HER2-expression IHC 1+, 2+, 3 + vs. HER2-zero IHC 0) were conducted using nonparametric statistical tests. Additionally, the correlation between tumor SUVmax and HER2 expression status was analyzed, and the HER2 PET metastasis-positive rate at the patient level in metastatic urothelial carcinoma was determined.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Twenty-five patients (mean age, 65.6 years ± 11.1 [SD]); 18 men) with urothelial carcinoma were enrolled. HER2 status in primary tumor was confirmed IHC 0 in four cases, IHC 1 + in three cases, IHC 2 + in six cases, IHC 3 + in three cases, and unknown in seven cases with potential HER2 expression. One patient with ureterostomy recurrence had HER2 IHC 1+, while another case was confirmed IHC 2 + through biopsy of metastatic lesion. In 16 participants with urothelial carcinoma, the SUVmax of HER2-positive primary tumors (IHC 2 + and 3+, n = 9) were higher than those of HER2-negative tumors (IHC 0 and 1+, n = 7) (median SUVmax, 7.07 ± 0.69 vs. 4.48 ± 1.14, p = 0.042) on [68Ga]Ga-HER2 affibody PET/CT. Additionally, a similar difference was observed between the HER2-expression group (IHC 1+, 2+, 3+, n = 12) and the HER2-zero group (IHC 0, n = 4) (median SUVmax, 6.97 ± 0.70 vs. 2.85 ± 0.19, p = 0.001). Primary tumors in 13 of the 16 patients were semi-quantitatively measurable on FDG PET/CT imaging, with no significant difference in FDG SUVmax between the HER2-positive and HER2-negative group (7 HER2-positive vs. 6 HER2-negative; median SUVmax: 19.56 ± 5.02 vs. 19.10 ± 3.13, p = 0.731). Spearman correlation analysis revealed a positive correlation between HER2 PET SUVmax and HER2 expression levels in primary urothelial carcinoma (R = 0.727, p = 0.001), whereas no correlation was found between FDG SUVmax ","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2782-2791"},"PeriodicalIF":8.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on Terbium-149: advancing preclinical research in targeted alpha therapy.","authors":"Serkan Kuyumcu, Yasemin Şanlı","doi":"10.1007/s00259-025-07151-z","DOIUrl":"10.1007/s00259-025-07151-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2759-2760"},"PeriodicalIF":8.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of cerebral amyloid angiopathy with ipsilateral tau and contralateral amyloid PET uptake related to cadaveric dura mater implanted in childhood.","authors":"Yuki Hatakeyama, Atsushi Michael Kimura, Shintaro Tsuboguchi, Mikhail Ratanov, Kosei Nakamura, Masahiro Hatakeyama, Yukimi Nakamura, Masaki Watanabe, Yoshihiro Murakami, Yuko Saito, Shigeo Murayama, Kensaku Kasuga, Takeshi Ikeuchi, Hironaka Igarashi, Osamu Onodera, Hitoshi Shimada","doi":"10.1007/s00259-024-07030-z","DOIUrl":"10.1007/s00259-024-07030-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2737-2739"},"PeriodicalIF":8.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]-fluorocholine long-axial-field of view PET-CT accurately localises intrathyroid parathyroid adenoma in 5-month pregnant patient.","authors":"Beverley F Holman,Tamar Willson,Jane Edwards,Bruno Ferreira,Piyumi Wijewickrama,Thomas Wagner","doi":"10.1007/s00259-025-07417-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07417-6","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"40 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144320330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Added value of multiparametric MRI for diagnosing subcentimeter functional adrenal nodules in primary aldosteronism using CXCR4-targeted PET/MRI.","authors":"Xiaoli Meng,Zhiyong Quan,Linni Fan,Mingru Zhang,Guiyu Li,Mengwei Xu,Jia Wang,Wenhui Ma,Weidong Yang,Bo Yang,Jing Wang,Fei Kang","doi":"10.1007/s00259-025-07415-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07415-8","url":null,"abstract":"OBJECTIVEThis study aims to evaluate the clinical utility of 68Ga-pentixafor PET/MRI in diagnosing primary aldosteronism (PA) in functional adrenal nodules, with a particular focus on subcentimeter nodules. Additionally, the diagnostic performance of integrated PET/MRI is compared to single-modality PET imaging.METHODSA total of 62 patients with clinical suspicion of PA were enrolled from a tertiary hospital in China. Prior to adrenalectomy, all patients underwent 68Ga-pentixafor PET/MRI, followed by CXCR4 and CYP11B2 immunohistochemical analysis post-surgery. Adrenal lesions were stratified into two size groups: ≥ 1 cm and < 1 cm. Quantitative PET parameters, including SUVmax, SUVmean, and lesion-to-liver uptake ratio (LLR), were evaluated alongside MRI parameters such as outphase/inphase signal ratio (OIR), relative percent washout (RPW), T2-weighted image intensity, apparent diffusion coefficient (ADC). Receiver operating characteristic (ROC) curve analysis was performed to establish diagnostic thresholds. Comparative analyses were conducted between single-modality PET and integrated PET/MRI for diagnostic accuracy.RESULTSAmong 62 patients, 74 adrenal lesions were confirmed pathologically, comprising 37 aldosterone-producing adenomas (APA, ≥ 1 cm), 21 aldosterone-producing micronodules (micro-APA, < 1 cm), and 16 non-functioning adenomas (NFA). Key PET/MRI parameters, including SUVmax, SUVmean, LLR, OIR, and RPW, showed significant differentiation between functional adrenal nodules and normal adrenal glands (P < 0.001). For nodules ≥ 1 cm, the PET SUVmax threshold of 7.87 achieved a sensitivity of 92.3% and specificity of 95.0% for APA diagnosis. For nodules < 1 cm, the PET SUVmax threshold of 6.49 yielded a sensitivity of 68.8% and specificity of 83.3% for micro-APA diagnosis. Integrated PET/MRI significantly improved the diagnostic sensitivity for PA subcentimeter nodules from 68.8% (with PET alone) to 87.5%, and increased the area under the ROC curve from 0.760 to 0.854, with no significant reduction in diagnostic specificity.CONCLUSION68Ga-Pentixafor PET/MRI demonstrated high diagnostic accuracy for functional adrenal nodules in PA, particularly enhanced sensitivity for subcentimeter nodules compared to PET alone.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"600 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144320333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring structure-function coupling in alzheimer's disease: bridging neuroimaging, AI, and policy for future insights.","authors":"Xun Wang,Yixin Jiang,Yifan Dong,Qian Zhu,Yan Zhao,Shuo Zhang","doi":"10.1007/s00259-025-07389-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07389-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"25 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144319755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lee A. Grant & Nyree Griffin (Authors). Grainger & Allison's Diagnostic Radiology Essentials, 3rd Edition. Elsevier, 2025, ISBN: 978-0-323-93605-7.","authors":"Luigi Mansi","doi":"10.1007/s00259-025-07421-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07421-w","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"20 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144319735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An exploratory assessment of early and delta PET radiomic features for outcome prediction in locally advanced cervical cancer.","authors":"Anita Florit,Wyanne A Noortman,Nicolò Bizzarri,Tina Pasciuto,Vanessa Feudo,Salvatore Annunziata,Lioe-Fee de Geus-Oei,Elisabeth Pfaehler,Ronald Boellaard,Maria Antonietta Gambacorta,Gian Franco Zannoni,Gabriella Ferrandina,Evis Sala,Giovanni Scambia,Vittoria Rufini,Floris H P van Velden,Angela Collarino","doi":"10.1007/s00259-025-07405-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07405-w","url":null,"abstract":"PURPOSEThis study investigated whether radiomic features extracted from [18F]FDG-PET scans acquired before and two weeks after neoadjuvant treatment, and their variation, provided prognostic parameters in locally advanced cervical cancer (LACC) patients treated with neoadjuvant chemo-radiotherapy (CRT) followed by radical surgery.METHODSWe retrospectively included LACC patients referred to our Institution from 2010 to 2016. [18F]FDG-PET/CT was performed before neoadjuvant CRT (baseline) and two weeks after the start of treatment (early). Radiomic features were extracted after semi-automatic delineation of the primary tumour, on baseline and early PET images. Delta radiomics were calculated as the relative differences between baseline and early features. We performed 5-fold cross-validation stratified for recurrence and cancer-specific death, integrating dimensionality reduction of the radiomic features and variable hunting with importance within the folds. After supervised feature selection, radiomic models with the best-performing features for each timepoint, as well as clinical models and combined clinico-radiomic models, were built. Model performances are presented as C-indices, for prediction of recurrence/progression (disease-free survival, DFS) and cancer-specific death (overall survival, OS).RESULTS95 patients were included. With a median follow-up of 76.0 months (95% CI: 59.5-82.1), 31.6% of patients had recurrence/progression and 20.0% died of disease. None of the models could predict DFS (C-indices ≤ 0.72). Model performances for OS yielded slightly better results, with mean C-indices of 0.75 for both the radiomic and combined model based on early features, 0.79 and 0.78 for the radiomic and combined model derived from delta features, and 0.76 for the clinical models.CONCLUSION[18F]FDG-PET early and delta radiomic features could not predict DFS in patients with LACC treated with neoadjuvant CRT followed by radical surgery. Although slightly improved performances for the radiomic and combined models were observed in the prediction of OS compared to the clinical model, the added value of these parameters and their inclusion in the clinical practice seems to be limited.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"40 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144320259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington's disease.","authors":"Aline Delva,Michel Koole,Kim Serdons,Guy Bormans,Mette Skinbjerg,Vinod Khetarpal,Longbin Liu,Jonathan Bard,Robert Doot,John H Warner,Swati Sathe,Cristina Sampaio,Andrew Wood,Koen Van Laere,Wim Vandenberghe","doi":"10.1007/s00259-025-07394-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07394-w","url":null,"abstract":"PURPOSE[11C]CHDI-00485180-R ([11C]CHDI-180R) is a novel PET radioligand developed to image aggregated mutant huntingtin (mHTT). Data from mouse models of Huntington's disease (HD) and biodistribution studies in healthy volunteers suggested that [11C]CHDI-180R is a promising candidate for in vivo determination of cerebral aggregated mHTT levels using PET. In the iMagemHTT study reported here, we investigated [11C]CHDI-180R kinetic properties and suitability to quantify aggregated mHTT in brains of people with HD (pwHD).METHODSA total of 12 pwHD (53.7 ± 6.9y, 5 M/ 7 F, Shoulson-Fahn stage 2) and 12 healthy controls (HC; six young [26.8 ± 3.2y], 2 M/ 4 F; six age-matched [53.7 ± 6.1y],2 M/ 4 F) were included. We conducted dynamic 90 min [11C]CHDI-180R PET imaging with arterial sampling and radiometabolite quantification, and delineated volumes of interest (VOIs) using individual 3D T1-MRI. We calculated total distribution volumes (VT) using 2-compartment modelling (2TCM) as well as Logan graphical analysis and determined distribution volume ratios relative to cerebellum (DVRCBL). We applied partial volume correction, and assessed test-retest variability in pwHD.RESULTSVT showed considerable intersubject variability among HC (VT(cortex) = 0.68 ± 0.22) and pwHD (VT(cortex) = 0.75 ± 0.26), without any regional significant differences between the groups. VT test-retest variability was high if test and retest scans were performed on the same day, but low (< 10%) if performed one week apart. DVRCBL showed significantly higher [11C]CHDI-180R relative binding in frontal, temporal, parietal, occipital and composite cortex VOIs (average increase 19.5 ± 6.1%) in pwHD than age-matched HC.CONCLUSION[11C]CHDI-180R VT showed high intersubject variability and relatively low signal-to-background ratio. However, significant differences were found between pwHD and HC using cerebellum as pseudo-reference region.REGISTRATIONEudraCT 2018-001862-41 clinicaltrials.gov NCT03810898 https://clinicaltrials.gov/study/NCT03810898?term=NCT03810898&rank=1.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"5 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}